- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05380804
Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
Comparison of Cutaneous Silent Period Parameters in Patients With Primary Sjögren's Syndrome With the Healthy Population and Determination of Its Relationship With Clinical Parameters
Primary Sjögren's syndrome (pSS) is a chronic, immune-mediated inflammatory disease mainly characterized by exocrine gland involvement. Beyond the wide heterogeneity in clinical presentation, neurological manifestation is one of the important systemic involvement of pSS. The prevalence of neurological involvement varies widely from 10% to 60% in different series.
Small fiber neuropathy (SFN) as a popular clinical entity in recent years targets nociceptive thinly myelinated A-delta and unmyelinated C-fiber nerves and is frequently associated with burning and allodynic pain. Previous studies have demonstrated that SFN is frequently seen in patients with pSS and has an important clinical importance because it cannot be detected by routine electrophysiological studies. Various methods can be used in the detection of SFN, and cutaneous silent period (CSP) measurement is gaining popularity recently due to its non-invasiveness and practical fashion.
In this study, the investigators aimed to compare CSP parameters as an indicator of SFN in patients with pSS and in the healthy population and to reveal its relationship with clinical parameters.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pendik
-
Istanbul, Pendik, Turkey, 34899
- Marmara University Pendik Education and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being between the ages of 18-65
- For the patient group, patients followed up in accordance with the 2016 ACR/EULAR primary Sjögren's Syndrome classification criteria
Exclusion Criteria:
- Any comorbidities that may cause neuropathy
- Any drugs that may cause neuropathy
- Chronic alcohol consumption
- A history of disease that may affect the central nervous system
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with primary Sjögren's syndrome
Cutaneous silent period measurement was performed in patients with the primary Sjögren's syndrome classified according to the 2016 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) criteria.
|
CSP recordings are performed in the upper extremities using the same surface bar recording electrodes.
Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms).
Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle.
During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed.
CSP latency and duration are calculated and recorded.
CSP latency is defined as the time between the stimulation and the onset of the silent period.
CSP duration is calculated as the time interval between the beginning and end of the CSP.
|
Healthy population
Cutaneous silent period measurement was also performed in healthy population.
|
CSP recordings are performed in the upper extremities using the same surface bar recording electrodes.
Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms).
Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle.
During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed.
CSP latency and duration are calculated and recorded.
CSP latency is defined as the time between the stimulation and the onset of the silent period.
CSP duration is calculated as the time interval between the beginning and end of the CSP.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparing the prevalence of the small fiber neuropathy in both groups
Time Frame: At baseline
|
Cutaneous silent period measurements are done for detecting small fiber neuropathy in both groups.
The latency and duration of CSP are recorded.
|
At baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between the number of the patients with small fiber neuropathy and score of the clinical disease severity
Time Frame: At baseline
|
For assessing clinical disease severity, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is used.
The correlation between ESSPRI scores and CSP parameters is investigated.
This assessment is done for only pSS group.
|
At baseline
|
Correlation between the number of the patients with small fiber neuropathy and scores of quality of life assessment.
Time Frame: At baseline
|
For assessing quality of life, Short Form-36 (SF-36) is used.
The correlation between SF-36 scores and CSP parameters is investigated.
This assessment is done for only pSS group.
|
At baseline
|
Correlation between the number of the patients with small fiber neuropathy and scores of mood assessments.
Time Frame: At baseline
|
For assessing mood, Hospital Anxiety and Depression Scale (HADS) is used.
The correlation between HADS scores and CSP parameters is investigated.
This assessment is done for only pSS group.
|
At baseline
|
Correlation between the number of the patients with small fiber neuropathy and number of patients with neuropathic pain
Time Frame: At baseline
|
For assessing neuropathic pain, Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) is used.
CSP parameters are compared between the patients with neuropathic pain according to the LANSS and the patients without neuropathic pain.
This assessment is done for only pSS group.
|
At baseline
|
Correlation between the number of the patients with small fiber neuropathy and number of patients with central sensitization
Time Frame: At baseline
|
For assessing central sensitization, Central Sensitization Inventory (CSI) is used.
CSP parameters are compared between the patients with central sensitization according to the CSI and the patients without central sensitization.
This assessment is done for only pSS group.
|
At baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ozge Kenis-Coskun, MD, Marmara University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Neuromuscular Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Peripheral Nervous System Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
- Small Fiber Neuropathy
Other Study ID Numbers
- 09.2021.111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Fiber Neuropathy
-
PNA Center for Neurological ResearchEisai Inc.Unknown
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
University of AlbertaCapital Health, CanadaTerminated
-
Johns Hopkins UniversityPfizerCompletedIdiopathic Small Fiber NeuropathyUnited States
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
JFK Medical CenterUnknownPeripheral NeuropathyUnited States
-
Aalborg University HospitalUniversity of Aarhus; Aalborg UniversityNot yet recruitingType 1 Diabetes | Neuropathy, Diabetic | Small Nerve Fiber Neuropathy
-
National Taiwan University HospitalUnknownChronic Kidney Disease | Small-Fiber NeuropathyTaiwan
-
Academisch Ziekenhuis MaastrichtCompletedSmall Fiber NeuropathyNetherlands
-
Academisch Ziekenhuis MaastrichtTerminated
Clinical Trials on cutaneous silent period (CSP) measurement
-
Cairo UniversityRecruiting
-
Centre Hospitalier Universitaire, AmiensUnknown